Litigation Details for SUPERNUS PHARMACEUTICALS, INC. v. ACTAVIS, INC. (D.N.J. 2014)

SUPERNUS PHARMACEUTICALS, INC. v. ACTAVIS, INC. (D.N.J. 2014)

Docket	2:14-cv-06102	Date Filed	2014-10-01
Court	District Court, D. New Jersey	Date Terminated	2017-03-16
Cause	35:271 Patent Infringement	Assigned To	Susan Davis Wigenton
Jury Demand	None	Referred To	Leda Dunn Wettre
Parties	SUPERNUS PHARMACEUTICALS, INC.
Patents	8,298,580; 8,663,683; 8,877,248; 8,889,191; 8,992,989
Attorneys	LIZA M. WALSH
Firms	Connell, Foley
Link to Docket	External link to docket

Details for SUPERNUS PHARMACEUTICALS, INC. v. ACTAVIS, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-10-01				External link to document

Supernus Pharmaceuticals v. Actavis, Inc. Litigation: Trokendi XR Patent Case 2:14-cv-06102

Last updated: August 31, 2026

Supernus Pharmaceuticals sued Actavis in the U.S. District Court for the District of New Jersey after Actavis filed an Abbreviated New Drug Application seeking approval for generic extended-release topiramate, the active ingredient in Trokendi XR. The case centered on U.S. Patent No. 8,663,683, which covered Supernus’s once-daily extended-release topiramate formulation. The litigation ended in a settlement rather than a publicly reported trial judgment. The settlement delayed Actavis generic entry until approximately June 2027, subject to the agreement’s terms and any applicable regulatory conditions. [1][2]

What drug and formulation were at issue in Supernus v. Actavis?

The dispute involved Trokendi XR, an extended-release oral capsule containing topiramate. Supernus markets Trokendi XR for the preventive treatment of migraine headache and as adjunctive therapy for partial-onset or primary generalized tonic-clonic seizures. [3]

Item	Information
Brand	Trokendi XR
Active ingredient	Topiramate
Dosage form	Extended-release capsule
Sponsor	Supernus Pharmaceuticals, Inc.
Generic applicant	Actavis, Inc.
ANDA	No. 205677
Court	U.S. District Court for the District of New Jersey
Case number	2:14-cv-06102
Primary asserted patent	U.S. Patent No. 8,663,683
Filing date	2014
Disposition	Settled and dismissed

Trokendi XR differs from immediate-release topiramate products, including Topamax, because its formulation is designed for once-daily administration and controlled release of topiramate over time.

What patent protected Trokendi XR in the Actavis litigation?

The principal patent asserted in the case was U.S. Patent No. 8,663,683, assigned to Supernus Pharmaceuticals. The patent claimed extended-release topiramate pharmaceutical compositions and related dissolution characteristics. Its claims were directed to formulation architecture rather than the basic topiramate molecule, which was already known and had lost compound-patent protection.

U.S. Patent No. 8,663,683

Patent characteristic	Detail
Patent number	8,663,683
Patent holder	Supernus Pharmaceuticals, Inc.
Technology	Extended-release topiramate formulation
Product relevance	Trokendi XR
Issue date	March 4, 2014
Approximate expiration	June 2027, including applicable patent-term adjustment
Litigation role	Asserted against Actavis ANDA 205677

The asserted patent was commercially important because it protected the delivery system that enabled once-daily Trokendi XR. A successful Paragraph IV challenge would have allowed Actavis to market a generic product before the patent’s expiration.

Supernus later obtained additional patents associated with Trokendi XR. Those later-issued patents were separate from the core 2014 Actavis complaint and expanded the Orange Book patent estate for the product.

Why did Supernus sue Actavis over ANDA 205677?

Actavis submitted an ANDA containing a Paragraph IV certification alleging that the relevant Supernus patent was invalid, unenforceable, or would not be infringed by the proposed generic product. A Paragraph IV certification is an assertion that an Orange Book-listed patent does not lawfully block FDA approval of the ANDA.

Supernus filed the infringement action within the statutory 45-day period after receiving Actavis’s Paragraph IV notice. The filing triggered the Hatch-Waxman litigation framework and imposed an automatic 30-month stay on FDA approval of the ANDA, unless the case was resolved earlier or the court ordered otherwise. [4]

The case therefore involved two linked questions:

1. Whether Actavis’s proposed extended-release topiramate product would infringe the asserted claims.
2. Whether those claims were valid and enforceable in view of the prior art and the patent’s prosecution history.

What were the main patent-infringement and validity issues?

The dispute focused on formulation claims, not the topiramate active ingredient itself.

Infringement issues

Supernus’s infringement theory was based on the structure and release profile of Actavis’s proposed generic extended-release formulation. The relevant analysis likely turned on whether the ANDA product included the claimed combination of immediate-release and extended-release components and met the patent’s specified dissolution parameters.

Under Hatch-Waxman law, the filing of an ANDA can constitute an artificial act of infringement under 35 U.S.C. § 271(e)(2). The court evaluates the proposed product based largely on the ANDA and related materials, rather than waiting for commercial manufacture and sale. [5]

Validity issues

Actavis’s Paragraph IV position placed validity defenses before the district court. The principal potential defenses for a formulation patent of this type included:

• Obviousness under 35 U.S.C. § 103;
• Lack of written description under 35 U.S.C. § 112;
• Lack of enablement;
• Anticipation under 35 U.S.C. § 102;
• Claim construction disputes concerning release rates and formulation components;
• Enforceability issues based on prosecution conduct.

The public record does not show a final merits decision invalidating the asserted patent in this action. The litigation was resolved by settlement.

When was the Supernus v. Actavis case settled?

The parties resolved the dispute before a final trial judgment. The settlement permitted Actavis to enter with a generic version of Trokendi XR around June 2027, corresponding broadly to the expected expiration period of the principal patent estate. Public disclosures did not provide all commercial terms of the agreement. [1][2]

The agreement did not represent an adjudication that the patent was valid or infringed. It was a negotiated resolution of the Hatch-Waxman dispute. As a result, the case does not provide a binding judicial finding on the ultimate validity of U.S. Patent No. 8,663,683.

What was the effect of the settlement on generic entry?

The settlement materially reduced the immediate risk of an Actavis launch. Instead of receiving approval and launching shortly after the 30-month stay or prevailing in litigation, Actavis was restricted to the negotiated entry date.

Generic launch scenarios

Scenario	Commercial effect
Settlement-compliant entry	Actavis launches around June 2027
Earlier negotiated entry	Possible only if authorized by the settlement or triggered by specified events
Supernus patent invalidated in separate litigation	Could accelerate generic entry, subject to FDA approval
Patent expiration without competing entry	Actavis and other applicants may launch after expiration
FDA approval delayed	Patent settlement date would not itself guarantee immediate commercialization

The settlement date should not be treated as a guaranteed market-entry date for every generic applicant. Other ANDA sponsors may have different certifications, separate litigation outcomes, or non-infringing formulations.

What was the Orange Book status of Trokendi XR?

FDA Orange Book listings identified patents associated with Trokendi XR. The original Actavis action concerned the patent protection asserted against ANDA 205677. Supernus later added patents to the product’s broader patent estate as additional formulation and manufacturing protections issued.

The Orange Book does not itself determine whether a listed patent is valid. It identifies patents that the NDA holder represents as claiming the drug, formulation, or approved method of use. Generic applicants must address listed patents through Paragraph I, II, III, or IV certifications, or through a section viii statement for patents directed only to methods of use. [6]

For Trokendi XR, formulation patents were more significant than method-of-use patents because the commercial differentiation centered on extended release and once-daily dosing.

What FDA exclusivity protected Trokendi XR?

Trokendi XR did not receive five-year new chemical entity exclusivity because topiramate was an established active ingredient. Its regulatory protection depended primarily on formulation patents, the Hatch-Waxman 30-month stay, and any applicable FDA exclusivity associated with the approval or clinical data package.

Protection type	Relevance
New chemical entity exclusivity	Generally unavailable because topiramate was previously approved
Three-year clinical-investigation exclusivity	Potentially relevant only if FDA determined that qualifying new clinical investigations supported approval
Pediatric exclusivity	Could add six months if separately granted
Patent protection	Central protection for the extended-release formulation
30-month stay	Delayed FDA approval of the challenged ANDA during litigation

The patent settlement, rather than a new chemical entity exclusivity period, was the principal mechanism delaying Actavis’s entry.

How strong was the Trokendi XR patent estate?

The estate was commercially meaningful but structurally narrower than a compound-patent estate. Its strength rested on formulation specificity, Orange Book listing, and the cost and timing of designing around the claimed release profile.

Strengths

• The patent covered the differentiated extended-release delivery system.
• Trokendi XR had no active compound patent barrier because topiramate was an older molecule.
• The asserted patent was issued before the litigation began.
• The Paragraph IV filing created a legally enforceable basis for early litigation.
• The settlement delayed the named challenger’s entry until the approximate patent-expiration period.

Limitations

• Formulation patents generally face greater design-around risk than compound patents.
• Validity depended on claim scope, prior-art combinations, and the technical significance of the release profile.
• A settlement did not establish enforceability or validity through a final judgment.
• Other generic applicants could pursue different formulations or certifications.
• Later patents may have different expiration dates and claim limitations, creating a fragmented protection profile.

The estate was stronger against a direct copy of the claimed extended-release architecture than against a materially different controlled-release formulation.

Did the case involve biosimilar risk?

No. Trokendi XR is a small-molecule topiramate product, not a biologic. The relevant competitive pathway was an ANDA for a generic drug, not a biosimilar application under the Public Health Service Act.

The principal risks were:

• Paragraph IV invalidity or non-infringement litigation;
• Formulation design-arounds;
• Post-settlement generic entry;
• Multiple generic applicants entering after the relevant patent barriers;
• Price erosion after extended-release topiramate competition begins.

Which companies challenged Trokendi XR exclusivity?

Actavis was the challenger identified in case 2:14-cv-06102. Actavis’s generic business later became part of broader corporate transactions involving Allergan and Teva, but the litigation must be analyzed based on Actavis’s status when the ANDA and complaint were filed.

The case does not establish that Actavis was the only potential future competitor. Other ANDA applicants could challenge the same patents independently, use a different certification strategy, or wait for patent expiration.

What patent litigation affects Trokendi XR commercial exposure?

The Actavis case reduced near-term litigation risk but did not remove all long-term exposure. The commercial risk profile has three phases:

Period	Risk profile
Before settlement entry date	Supernus benefits from the negotiated restriction on Actavis
Around patent-expiration period	Generic launch risk increases sharply
After broad generic entry	Trokendi XR faces price erosion, formulary substitution, and volume loss

Revenue exposure depends on the size of the Trokendi XR franchise, payer coverage, physician switching behavior, generic substitutability, and whether additional patent claims remain enforceable at the time of launch. A settlement that delays one applicant does not provide the same protection as a final judgment upholding a broad patent estate against all potential entrants.

What is the legal significance of the case?

Supernus v. Actavis is principally a Hatch-Waxman settlement case. Its business significance lies in the negotiated generic-entry restriction, not in a reported judicial ruling establishing the validity or infringement of the asserted patent.

The case confirms several practical points for pharmaceutical patent strategy:

1. A formulation patent can support substantial litigation leverage even after compound protection has expired.
2. A Paragraph IV notice can force a rapid infringement action and delay FDA approval through the 30-month stay.
3. Settlement timing can determine several years of branded-product exclusivity.
4. The absence of a merits judgment leaves later challengers free to contest validity or infringement.
5. Later Orange Book patents may preserve some protection after the first litigation, but their claims and expiration dates require separate analysis.

Key takeaways

• The case involved Trokendi XR, Supernus’s extended-release topiramate product.
• Actavis challenged the product through ANDA No. 205677 and a Paragraph IV certification.
• U.S. Patent No. 8,663,683 was the principal patent asserted in the 2014 litigation.
• The case settled before a final merits judgment.
• Actavis’s negotiated generic entry was delayed until approximately June 2027.
• The dispute concerned formulation protection, not topiramate compound protection.
• Trokendi XR faces generic, not biosimilar, competition.
• The settlement reduced immediate entry risk but did not conclusively validate the patent estate.
• Later patents and separate ANDA challenges must be analyzed independently.

FAQs about Supernus Pharmaceuticals v. Actavis

What was Actavis’s ANDA number for generic Trokendi XR?

Actavis filed ANDA No. 205677 for a generic extended-release topiramate product corresponding to Trokendi XR.

Did Supernus win a trial against Actavis?

No final merits victory is reflected in the public disposition of case 2:14-cv-06102. The parties settled the litigation before a publicly reported final trial judgment.

What patent expiration date mattered most for Trokendi XR?

U.S. Patent No. 8,663,683 had an expiration period in approximately June 2027 after applicable patent-term adjustment. The effective generic-entry date also depended on the settlement and any other enforceable patents.

Can a generic company launch Trokendi XR before June 2027?

A company could potentially launch earlier if it achieved a separate litigation victory, obtained a license, relied on a non-infringing formulation, or benefited from a regulatory or legal event that removed the relevant barrier. The Actavis settlement itself delayed Actavis’s agreed entry.

Is Trokendi XR protected by a patent on topiramate?

No. The key protection was directed to the extended-release formulation and delivery characteristics. Topiramate was an older active ingredient with compound protection no longer providing the principal barrier to competition.

References

1. Supernus Pharmaceuticals, Inc. (2014). Complaint, Supernus Pharmaceuticals, Inc. v. Actavis, Inc., No. 2:14-cv-06102, U.S. District Court for the District of New Jersey.

2. Supernus Pharmaceuticals, Inc. (2015). Annual report and public disclosures concerning Trokendi XR patent litigation and Actavis settlement. SEC filings.

3. U.S. Food and Drug Administration. (2024). Trokendi XR prescribing information. FDA.

4. Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

5. Hatch-Waxman Act, 35 U.S.C. § 271(e)(2).

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.